NCT04556734Phase 2Completed
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata
In the register
The register attaches this trial to Etrasimod (Pfizer), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Pfizer
- Participants (registry)
- 80
- Start
- July 2020
- Primary completion
- June 2023
- Study completion
- June 2023
- Last registry update
- June 2024
- Countries
- United States, Canada
Conditions studied: Alopecia Areata
Interventions: Etrasimod, APD334, Etrasimod, APD334, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.